BIODESIX (BDSX) Stock News

Biodesix (NASDAQ:BDSX) has announced a one-for-twenty reverse stock split effective September 15, 2025. The split will reduce the company's outstanding shares from approximately 156 million to 8 million, while maintaining the same authorized shares and par value.

The reverse split was approved by stockholders on May 20, 2025, and will be executed through Computershare Trust Company. Stockholders' percentage ownership will remain unchanged except for fractional shares, which will be paid in cash. All equity incentive plans, stock options, restricted stock units, and warrants will be proportionally adjusted.

Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced that CFO Robin Cowie will participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference on September 11, 2025, in New York. The CFO will be available for one-on-one meetings with investors during the conference.

Biodesix (Nasdaq: BDSX) has been designated as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. The company played a crucial role in validating Thermo Fisher's Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, which received FDA approval in July 2025.

Through its Development Services division, Biodesix provided validation studies and data generation support for regulatory submission using its design-controlled laboratory processes and quality management systems. The company aims to expand its molecular diagnostic and NGS testing capabilities in tissue-based profiling.

Biodesix will participate in upcoming presentations about the NGS precision oncology solution at the CAP TODAY webinar on August 27, 2025, and the College of American Pathologists Annual Meeting on September 15, 2025.

Biodesix (NASDAQ: BDSX) reported strong Q2 2025 financial results with total revenue of $20.0 million, up 12% year-over-year. The company achieved an impressive 80% gross margin, a 150-basis point improvement from Q2 2024. Lung Diagnostic Testing revenue increased 8% to $17.9 million, while Development Services revenue grew 53% to $2.1 million.

Key operational highlights include expanding their sales team to 74 representatives (21% increase), achieving over 100% growth in primary care ordering of lung diagnostic tests, and reaching $12.5 million in development services contracts. Despite these improvements, the company reported a net loss of $11.5 million. Biodesix reaffirmed its full-year 2025 revenue guidance of $80-85 million and expects to achieve Adjusted EBITDA positivity in Q4 2025.

Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on August 12, 2025, at 4:30 PM ET in Boston, MA.

The presentation will be accessible via live webcast and available for replay in the Investors section of biodesix.com under "News & Events".

Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has scheduled its Q2 2025 financial results release for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET the same day to discuss results and provide business updates.

Management will conduct a Q&A session for analysts, and a webcast replay will be available on the investor website approximately two hours after the call concludes. Participants are encouraged to join 15 minutes before the start time.

Biodesix (NASDAQ: BDSX) has partnered with the Association of Pulmonary Advanced Practice Providers (APAPP) to launch the first CME-accredited educational programs focused on diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs. The collaboration aims to educate healthcare providers about innovative lung nodule risk assessment tools like the Nodify Lung blood-based tests and cancer treatment decision support testing such as IQLung blood-based tests. The initiative addresses the critical need for improved lung cancer detection, as lung cancer remains the deadliest cancer type, with 1 in 18 Americans expected to receive a diagnosis in their lifetime. The partnership focuses on empowering providers in both rural and metropolitan settings to better serve diverse patient populations despite resource limitations.

Biodesix (NASDAQ: BDSX) announced new data from the INSIGHT study on their VeriStrat Host Immune Classifier (HIC) test will be presented at the 2025 ASCO Annual Meeting. The study, involving over 5,000 NSCLC patients, demonstrates the test's ability to predict overall survival in non-small cell lung cancer patients receiving immunotherapy.

Key findings show that patients with VeriStrat Poor results had significantly improved survival when receiving combined immunotherapy and chemotherapy versus immunotherapy alone, with two-year survival rates more than tripling. Patients with VeriStrat Good results showed comparable survival with either treatment. Preliminary results suggest potential applications for other solid tumors, with additional data expected later in 2025.

Biodesix (NASDAQ: BDSX), a diagnostic solutions company, has announced its participation in two upcoming investor conferences. The company will attend the 22nd Annual Craig-Hallum Institutional Investor Conference for one-on-one meetings on May 28, 2025, in Minneapolis, MN. Additionally, Biodesix will present at the 45th Annual William Blair Growth Stock Conference on June 4, 2025, at 9:20 AM CT in Chicago, IL. The William Blair conference presentation will be available via webcast and can be accessed through the Investors section of Biodesix's website under \"News & Events\".